CDT Equity Inc.

About CDT Equity Inc.

CDT Equity Inc. is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, it has evolved into a platform leveraging AI, solid-form chemistry, and asset repositioning to accelerate novel treatment development, aiming to create shareholder value through licensing, M&A, and transformative innovation.

Products & Services

Therapeutic Assets:High-potential therapeutic assets developed through scientific innovation and strategic partnerships.

Specialties

Artificial Intelligence Solid-Form Chemistry Asset Repositioning Therapeutic Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Asset Acquisition T: - FT: Asset Acquisition	A: 1005000 MR: - FA: $1,005,000 FAN: 1005000	D: 2025-10-17 FD: 2025-10-17	-

Asset Acquisition Latest

2025-10-17

$1.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

Freda Lewis-Hall

Chair of the Board of Directors & Chair of Nominating and Corporate Governance Committee

A

Andrew Regan

Chief Executive Officer

J

James Bligh

Chief Financial Officer

C

Chele Chiavacci Farley

Chair of Audit Committee

S

Simon Fry

Chair of Compensation Committee

J

Joanne Holland

Chief Scientific Officer

View 3 more team members with Pro

Unlock Full Team Directory

Recent News

CDT Equity Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised